



Cloud Dx

Biosign Technologies

Scott Jenkins, CEO



Annual Shareholders Meeting Presentation
September 12, 2011
Ontario, Canada

LIFIT



Forward Looking Statements

Cloud Dx

UFIT

BIO SIGN

BIO SIGN

This presentation contains forward-looking statements about Biosign and/or Cloud Dx and its business, business prospects, strategy and plans, including but not limited to statements regarding anticipated product development activities, market opportunities and financial information.

These statements involve substantial risks and uncertainties that could cause actual results or events to differ materially from our current expectations and the forward-looking statements included in this presentation.

For a discussion of the risk factors that could cause actual results to vary from these forward-looking statements, please see our filings with Canadian securities regulatory authorities at www.sedar.com. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which apply only as of the date of the presentation.

Cloud Dx Branding



The Company



The Technology

Ufit

The Product



Cloud Dx Branding




Worldwide Diabetes

DIABETES EXPENDITURE BY COUNTRY

FIGURE 5.2

Annual health expenditure for diabetes (ID) vs persons with diabetes in the 25 countries with the largest numbers of persons with diabetes in 2007



Source: *Diabetes Atlas 3rd Ed.*, © International Diabetes Federation, 2006

Worldwide Heart Disease

Cloud Dx


BIO SIGN

UFIT

BIO SIGN


Global Cardiovascular Disease Diagnostics Market to Reach US\$12.4 Billion by 2015.

*According to a New Report by Global Industry Analysts, Inc.



"Worldwide chronic obstructive pulmonary disease on the order of \$400 billion in 2010,"

Cost of cardiovascular disease in US to triple by 2030



<http://www.theheart.org/article/1176761.do>

Jan 25, 2011

UFIT - Technology




Cloud Validation



Secure Raw Data Transfer


Cloud Analysis **Wireless**
Raw Data Storage



Raw Signal

Measurement	Validation Standard
Sphygmo-manometer (Blood Pressure)	ANSI/AAMI SP10:2002
Sphygmo-glucometer (Blood Glucose)	ISO-15197:2003

Internet Device




Patient Portal



Circle of Care

Cloud Validation



Secure Raw Data Transfer

Raw Data Storage
Cloud Analysis **Wired**

Competitive advantage



	Blood Glucose	Accuracy >80%	Data Stored For Patient	Blood Pressure	Live data to Doc/Payers	Track Patient Over Time	Risk of infection or Death
Cloud Dx	X	X	X	X	X	X	
Roche (\$3b)	X	X	*				X
J & J (\$2.5b)	X	X	*				X
Bayer (\$1.5b)	X	X	*				X
Abbott (\$1.5b)	X	X	*				X

* A limited number of measurements can be stored on the meter

Market Model




\$0 lease and \$1/condition/day for patients; \$1/patient/day real time access for the Docs; \$1/patient/day real time access for the payers

Pay over \$120/mo Receive **NO** information

Receive **NO** information from external setting & don't trust Glucometer data

Strips hurt & meter data is read but often **NOT** recorded.



• \$1/day/patient



Population Dashboard


• \$1/day/patient



Patient Dashboard


Device Lease \$0.00

• \$1/day/Disease (BP)
• \$1/day/Disease (Glu)



Averages

• \$4+/day/patient



Trending over time



Patient HealthCare Utilization


Cloud Dx

BIO SIGN

UFIT

BIO SIGN

Healthcare Utilization



15% of Patients use
70% of the service
delivery cost

Percentage of
Patients

Cloud Dx

Market Model Specifics


Cloud Dx

BIO SIGN

UFIT

BIO SIGN

- Only Payers pay for the system (not available directly to consumers)
- About 100 Payers total in the world (most of the world is single payer)
- **5% OF PATIENTS** of any health system utilizes **40%** of the service delivery costs
- We primarily target the 1-15% of highest utilizers for interventional treatment or cost avoidance
- **\$0 COST** to roll-out and can cancel anytime
- Our system provides real-time cloud enabled dashboards and portals
- New revenue generating services can be activated for all existing subscriptions, so revenue can increase over time without a need for new installation
- A per Day rate means **UNLIMITED** testing for patients
- Deployments can be directly shipped to patient and auto provisioned
- Billing begins 30 days after shipment on a WW basis



Summary

Cloud Dx

BIO SIGN

UFIT

BIO SIGN

Great opportunity to impact healthcare market

- ❑ Cloud Diagnostics' non-invasive device with cloud calibration and analysis is a better approach
- ❑ Continually Securing IP and protecting trade secret algorithms is a competitive advantage
- ❑ We own all data gathered worldwide

Proven team and initial results

- ❑ Delivering products to paying customers with over 10 studies in progress
- ❑ Established early partnerships with enabling technologies.
- ❑ Top talent has been identified and prepared to assist with exponential growth

Seeking support to capture the opportunity

- ❑ Financing
- ❑ Building management and sales team
- ❑ Secure FDA Approval
- ❑ Activate multiple pilots with large payers & health systems worldwide.